KPTI vs SYK · rev $68.5M vs P/E 35, rev $6.59B
Karyopharm Therapeutics Inc (KPTI) versus Stryker Corporation (SYK) — a side-by-side from cached financials, not a winner call.
Karyopharm Therapeutics Inc (KPTI) is a biotechnology company listed on US.
Stryker Corporation (SYK) is a medical devices company listed on NYSE.
Latest reported KPTI revenue for 2026-06-30 was $68.5M. Net income was -$89.4M. Revenue was up 95.3% from 2026-03-31 to 2026-06-30. KPTI currently screens at market cap $205.6M.
Latest reported SYK revenue for 2026-06-30 was $6.59B. Net income was $1.28B. Revenue was up 9.5% from 2026-03-31 to 2026-06-30. SYK currently screens at market cap $115.45B and trailing P/E 34.9.
KPTI currently screens at market cap $205.6M. SYK currently screens at market cap $115.45B and trailing P/E 34.9.
Not investment advice. Open the KPTI and SYK stock pages for the full models.
Not investment advice.